|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.98 USD | +0.59% |
|
+28.94% | +182.29% |
| 07-28 | EARNINGS AND TRADING: Allergy Therapeutics names next executive chair | AN |
| 07-27 | Health Care Up Amid Deal Activity -- Health Care Roundup | DJ |
Company Valuation: Forte Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,882 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 287.02% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,882 | 1,882 | 1,882 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 287.02% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -19.4x | -18.9x | -18.5x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 1.2x | -6.81x | -7.94x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -20.7x | -17.5x | -14.7x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -3.965 | -4.075 | -4.17 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -91.11 | -107.4 | -127.6 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -91.11 | -107.4 | -127.6 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 76.98 | 76.98 | 76.98 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 24,447 | - | - |
| Announcement Date | 31/03/22 | 31/03/23 | 18/03/24 | 28/03/25 | 31/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -19.41x | - | - | - | 1.88B | |
| 20.76x | 6.35x | 13.89x | 1.53% | 55.23B | |
| 31.7x | 7.83x | 24.1x | 0.05% | 53.75B | |
| -18.35x | 4.4x | -7.71x | -.--% | 23.48B | |
| -39.73x | 12.6x | -37.13x | -.--% | 22B | |
| 24.86x | 4.85x | 12.85x | -.--% | 19.78B | |
| 24.09x | 4.69x | 15.26x | -.--% | 17.44B | |
| -736.67x | 34.86x | -3924.15x | -.--% | 14.66B | |
| 17.61x | 5.1x | 11.9x | -.--% | 14.07B | |
| 39.36x | 15.8x | 40.68x | 0.09% | 13.02B | |
| Average | -65.58x | 10.72x | -427.81x | 0.19% | 23.53B | |
| Weighted average by Cap. | -32.37x | 9.08x | -236.65x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
